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Phytotherapy Research. 2019;33:845–855.Plants of the Brassicaceae family are well‐known for containing the glucosinolate
myrosinase system, which is able to release isothiocyanates after plant biotic and abi-
otic lesions. Erucin (ERU; 1‐isothiocyanato‐4‐(methylthio)‐butane), an isothiocyanate
particularly abundant in arugula (Eruca sativaMill., Eruca vesicaria L., etc.), derives from
the hydrolysis of the glucosinolate glucoerucin by the enzyme myrosinase. Many
other natural isothiocyanates influence cancer cells and, in particular, induce antipro-
liferative effects at relatively high concentrations. Similar antiproliferative effects
have also been shown by the newly emerging gasotransmitter hydrogen sulfide
(H2S) and by H2S‐releasing compounds. In a previous study, our group demonstrated
that isothiocyanates release H2S in biological environments. In this work, we demon-
strated the H2S‐donor properties of ERU in pancreatic adenocarcinoma cells (AsPC‐1)
and delineated its profile as a chemopreventive or anticancer agent. Indeed, ERU
showed significant antiproliferative effects: ERU inhibited AsPC‐1 cell viability at
relatively high concentrations (30–100 μM). Moreover, ERU inhibited cell migration,
altered the AsPC‐1 cell cycle, and exhibited proapoptotic effects. Finally, ERU
inhibited ERK1/2 phosphorylation. This mechanism is particularly important in
AsPC‐1 cells because they are characterized by a mutation in KRAS that determines
KRAS hyperactivation followed by MAP‐kinase hyperphosphorylation, which plays a
pivotal role in pancreatic cancer proliferation, growth, and survival.
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AsPC‐1, erucin, hydrogen sulfide, isothiocyanates, pancreatic cancer1 | INTRODUCTION
In recent years, the anticancer properties of dietary agents
have been widely investigated, and in particular, it has beena cells; AUC, area under the curv
al‐regulated kinase; ERU, erucin; F
buffer solution; PEITC, phenethyl
1; WST, water‐soluble tetrazolium
wileyonlinelibrary.codemonstrated that the consumption of Brassicaceae vegetables
(crucifers), such as broccoli, cauliflower, cabbage, and rocket salad,
is associated with a lower risk of cancer (Fofaria, Ranjan, Kim, &
Srivastava, 2015).e; BITC, benzyl isothiocyanate; DADS, diallyl disulfide; DATS, diallyl trisulfide;
BS, foetal bovine serum; FI, fluorescence index; ITCs, isothiocyanates; MAPK,
isothiocyanate; RPMI, Roswell Park Memorial Institute; SFN, sulforaphane; U,
salt
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846 CITI ET AL.These edible plants contain high amounts of isothiocyanates (ITCs),
which are produced through the enzymatic hydrolysis of glucosinolates
by endogenous myrosinase and exhibit antiproliferative activity against
cancer in both cell culture and animal models (Nastruzzi et al., 2000).
In fact, some natural ITCs, such as sulforaphane (SFN), phenethyl
isothiocyanate, benzyl isothiocyanate (BITC), and erucin (ERU) derive
from Brassicaceae plants and have inhibitory effects on the growth
of several types of cultured cancer cells, including leukaemia, prostate
cancer, breast cancer, lung cancer, cervical cancer, and colorectal
cancer. Moreover, ITCs are well absorbed and highly bioavailable,
making them promising compounds for anticancer therapies (Fofaria
et al., 2015).
Many studies have demonstrated that ITCs exert anticancer
effects through different mechanisms of action, including promoting
cell cycle arrest and apoptosis, interacting with the Keap1‐Nrf2‐ARE
pathway and upregulating phase II detoxification enzymes (Fuentes,
Paredes‐Gonzalez, & Kong, 2015).
SFN is the most studied isothiocyanate in Brassicaceae vegetables
and has been particularly studied in broccoli and broccoli sprouts
(Clarke et al., 2011). However, ERU, an isothiocyanate structurally
related to SFN and typically present in high amounts in wild rocket
(Eruca sativaMill.), is still less studied. ERU is produced from its precur-
sor, the glucosinolate glucoerucin, by the plant enzyme myrosinase; a
myrosinase‐like thioglucosidase activity has been recognized in the
bacteria of the human gut. Notably, ERU is also produced in the
human body after the biotransformation of SFN through the reduction
of the sulfur atom (Melchini & Traka, 2010).
Recently, our group described some synthetic aryl isothiocyanates
as H2S‐donor agents, exhibiting significant effects on the cardiovascu-
lar system, attributable to the donation of H2S (Martelli et al., 2014).
Aside from these synthetic compounds, other natural ITCs, such
as allyl isothiocyanate, which is highly present in black mustard
(Brassica nigra L.), 4‐hydroxybenzyl isothiocyanate, which is highly
present in white mustard (Sinapis alba L.), benzyl isothiocyanate, which
is highly present in garden cress (Lepidium sativum L.), SFN, and ERU
have also been described as slow H2S‐releasing compounds (Citi
et al., 2014; Lucarini et al., 2018).
H2S is a well‐known endogenous gasotransmitter that plays piv-
otal roles in the cardiovascular system and respiratory system and in
regulating cell growth. Recent studies have indicated that H2S has
two opposite effects on cancer cell growth that may be due to the
concentration of H2S and the time of exposure to cancer cells. This
behaviour, defined as “hormetic,” has been confirmed in different
studies reporting that endogenous H2S, as well as the exposure to
low levels of exogenous H2S or H2S‐donors for a short duration, could
have antiapoptotic effects in cancer cells, promoting and maintaining
cancer growth (Hellmich, Coletta, Chao, & Szabo, 2015). In contrast,
treatment with a relatively high concentration of H2S‐donors for a
long time has been reported to inhibit cancer cell growth in different
types of tumours, thus indicating that slow‐releasing H2S donors could
be an innovative and promising therapeutic strategy in antineoplastic
therapy (Calderone, Martelli, Testai, Citi, & Breschi, 2016).
Interestingly, there is an intriguing overlap betweenmany anticancer
effects attributed to some ITCs and those exhibited by treatments
with some known H2S donors (De Cicco et al., 2017; Panza et al., 2015).Among the several types of cancer, pancreatic adenocarcinoma is
one of the most lethal forms, and although substantial progress has
been made in understanding the biology of this cancer, it still has an
extremely poor prognosis.
For this reason, in this paper, the AsPC‐1 human pancreatic adeno-
carcinoma cell linewas selected. AsPC‐1 cells are particularly aggressive
due to their molecular and genetic status; in fact, they are characterized
by the lack of the LKB1 tumour suppressor protein causing a particular
resistance to apoptosis and by homozygote mutations in the KRAS
gene, promoting the constitutive activation of this kinase (Deer et al.,
2010). On this basis, in this study, we focused our attention on the anti-
cancer effects of ERU, a natural isothiocyanate with H2S donor proper-
ties, to investigate the following primary endpoints: its ability to enter
AsPC‐1 cells and to release H2S at the intracellular level, its capacity
to inhibit cell viability and migration, its ability to alter the AsPC‐1 basal
cell cycle, and its ability to exert proapoptotic effects. Finally, a possible
mechanism of action was investigated to evaluate the involvement
of the MAPK/ERK pathway in the anticancer properties of ERU.2 | MATERIALS AND METHODS
2.1 | Isolation of natural ERU
Erucin was produced from natural glucoerucin by myrosinase‐catalysed
hydrolysis. The glucosinolate was purified from E. sativa Mill. seeds
stored in the Brassicaceae collection at CREA‐CI, Bologna, Italy (Lazzeri
et al., 2013). Glucoerucin was isolated as K+ salts from defatted seed
meal via extraction with boiling 70% ethanol followed by ion exchange
chromatography and gel filtration chromatography, as described previ-
ously (Franco et al., 2016). Isolated glucoerucin was analysed by HPLC‐
UV after enzymatic desulfation according to the ISO 9167‐1 method,
yielding 99% purity based on the peak area value and 96% purity based
on weight. Myrosinase, 36 U/ml, was isolated from ripe seeds of white
mustard (S. alba L.) as previously reported (Pessina, Thomas, Palmieri, &
Luisi, 1990) and stored at 4°C in sterile distilled water until use. One
myrosinase unit (U) is defined as the amount of enzyme that can hydro-
lyse 1 μmol sinigrin per min at a pH of 6.5 at 37°C. A total of 500 mg of
glucoerucin was hydrolysed in the presence of 25 U of myrosinase in
0.1 M potassium phosphate buffer, pH 6.5, for 2 hr at 37°C. ERU was
extracted three times with 50 ml dichloromethane using a 250 ml sep-
arating funnel. The collected organic phases were unified and concen-
trated at 37°C by a rotary evaporator under vacuum. The obtained
solution was dried using anhydrous Na2SO4 and filtered, and the
remaining dichloromethane was evaporated under a weak current of
nitrogen. ERU was finally identified by GC–MS analysis on a Bruker
GC 451 gas chromatograph equipped with an HP‐5 fused silica capil-
lary column (30 m by 0.25 mm inside diameter; 0.25 μm film thickness,
J&W Scientific Inc, Folsom, California) connected to a quadrupole mass
detector (Bruker Scion SQ Premium, Bruker Daltonics, Macerata, Italy).
The oven temperature was set at 60°C and maintained for 4 min. Then,
the temperature was programmed to rise from 60°C to 220°C at a rate
of 10°C min−1 and was finally held at 220°C for 4 min. The transfer line
was maintained at 280°C, and the ion source was maintained at 220°C.
Split injection (1:20) was applied, and the carrier gas flow (helium) was
CITI ET AL. 847set at 1 ml min−1. The mass spectrometer was operated in electron
impact mode at 70 eV, scanning the range of 10–250m/z, in a full scan
acquisition mode. Mass spectra were identified by matching the
recorded mass spectra with the NIST/EPA/NIH Mass Spectral
Database (NIST 11, Gaithersburg, Maryland). A dichloromethane
solution containing 0.2 mg/ml ERU and BITC (Sigma Aldrich 89983)
as an internal standard was analysed to estimate the purity of the final
natural ERU preparation. A response coefficient of 1.67 was calculated
by the ratio of the slope of the calibration curves of BITC (Sigma Aldrich
89983) and of ERU (Santa Cruz sc‐204741) dichloromethane solutions
in the concentration range of 0.05 ÷ 1 mg/ml.2.2 | Cell culture and cell viability assay
The human pancreas adenocarcinoma ascites metastasis cell line
AsPC‐1 (Sigma‐Aldrich, passage number 3, population doubling time
38–40 hr) was cultured in RPMI 1640 (Sigma‐Aldrich) supplemented
with 2 mM glutamine (Sigma‐Aldrich), 1 mM sodium pyruvate (Sigma‐
Aldrich), 10% foetal bovine serum (Sigma‐Aldrich), and 1% of
100 units/ml penicillin and 100 mg/ml streptomycin (Sigma‐Aldrich) in
tissue culture flasks at 37°C in a humidified atmosphere and 5% CO2.
AsPC‐1 cells were seeded onto 96‐well plates at a density of 104
cells per well. After 24 hr, to allow cell attachment, the medium was
replaced in each 96‐well plate, and the cells were treated for 72 hr
with ERU at the concentrations of 100, 30, 10 μM, or vehicle
(dimethyl sulfoxide [DMSO] 1%). At the end of each treatment, cell
viability was assessed using the cell proliferation reagent WST‐1
(Roche, Basel, Switzerland; Citi et al., 2018), which is cleaved to
formazan in living cells. WST‐1 was added at a ratio of 1:10 of the
total volume of the wells, and after 60 min of incubation at 37°C,
the absorbance was measured at 450 nm by a multiplate reader
(Enspire, Perkin‐Elmer, Waltham, Massachusetts, United States).2.3 | Evaluation of H2S release in AsPC‐1 cells
The evaluation of H2S release into the cytosol of AsPC‐1 cells was
assessed by the spectrofluorometric method as previously described
(Barresi et al., 2017). Briefly, AsPC‐1 cells were cultured up to approxi-
mately 90% confluence, and 24 hr before the experiment, cells were
seeded onto a 96‐well black plate at a density of 72 × 103 cells per well.
After 24 hr, the cells were preloaded with a 100 μM solution of
the fluorescent dye WSP‐1 (Washington State Probe‐1, Cayman
Chemical; Liu et al., 2011). WSP‐1 was first incubated with AsPC‐1
cells for 30 min (allowing cells to upload the dye), then the supernatant
was removed and replaced with a solution of the compounds to be
tested, a reference drug or vehicle (dimethyl sulfoxide, DMSO 1%).
The well‐known H2S‐releasing agent diallyl disulfide (DADS;
Benavides et al., 2007; Liang, Wu, Wong, & Huang, 2015) was
selected as a reference drug because it shows some physiochemical
similarities to ERU (relatively low molecular weight, no charge, lipophi-
licity). The tested compound ERU, at the following concentrations 10,
30, and 100 μM and DADS 100 μM were first dissolved in DMSO and
then diluted in buffer standard. This range of concentrations was
selected on the basis of the anticancer concentrations found in theliterature for several ITCs (Su et al., 2015). When WSP‐1 reacts with
H2S, it releases a fluorophore detectable by a spectrofluorometer at
λ = 465–515 nm (Peng et al., 2014). The increase in fluorescence
(expressed as fluorescence index = FI) was monitored for 45 min using
a spectrofluorometer (EnSpire, Perkin Elmer).
2.4 | Wound healing assay
AsPC‐1 cells (4 × 105 cells per well) were plated in six‐well tissue cul-
ture plates and grown to 90–95% confluence. After aspirating the
medium, the centres of the cell monolayers were scraped with a
200 μl pipette tip to create a denuded zone (gap) of consistent width.
Then, cellular debris was washed with phosphate buffer solution
(PBS), and cells were treated with ERU at concentrations of 10 and
30 μM. The wound closure was monitored and photographed every
24 hr for 72 hr with an Olympus inverted microscope and camera
(4x zoom). The gap was measured with ImageJ software.
2.5 | Analysis of cell cycle, caspase 3/7 activity,
mitochondrial potential, and ERK1/2 phosphorylation
2.5.1 | General conditions
AsPC‐1 cells were seeded, and after 24 hr, to allow cell attachment,
the medium was replaced, and the cells were treated for 72 hr with
30 μM ERU, 10 μM Paclitaxel (positive control for caspase 3/7
activity), or vehicle (DMSO 1%) or were not treated.
2.5.2 | Cell cycle assay
The distribution of the cell cycle was analysed by flow cytometry using
the Muse™ Cell Cycle Kit from EMD Millipore Bioscience. Cell cycle
analysis was performed according to the manufacturer's protocol.
AsPC‐1 cells were seeded into 6‐well plates at a density of 5 × 105
cells per well, and after incubation with the treatments (see general
conditions), the cells were washed with PBS, detached, and fixed with
1 ml ice‐cold 70% ethanol at −20°C for at least 3 hr. The cells were
then washed with PBS, and 1 × 106 cells were stained with 200 μL
of muse cell cycle reagent for 30 min at 37°C in the dark. Then, the
cells were analysed by the Muse™ Cell Analyzer.
2.5.3 | Caspase 3/7 activity
Caspase 3/7 activity was analysed by flow cytometry using the
Muse™ Caspase 3/7 Activity Kit from EMD Millipore Bioscience.
Caspase 3/7 activity was evaluated according to the manufacturer's
protocol. AsPC‐1 cells were seeded into 24‐well plates at a density
of 1 × 105 cells per well, and after incubation with the treatments
(see general conditions), the cells were detached, washed with PBS,
and resuspended at a concentration of 1 × 105 to 5 × 106 cells/ml in
the 1X assay buffer provided. Subsequently, 5 μl of Muse™ Caspase‐
3/7 Reagent working solution was added to 50 μl of cell suspension
and incubated at 37°C for 30 min. Then, 150 μl of Muse™ Caspase
7‐AAD working solution was added and incubated at 37°C for 5 min
protected from light; cells were analysed by the Muse™ Cell Analyzer.
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Mitochondrial potential was analysed by flow cytometry using the
Muse™ MitoPotential Assay Kit from EMD Millipore Bioscience. The
mitochondrial potential was evaluated according to the manufacturer's
protocol. AsPC‐1 cells were seeded onto 24‐well plates at a density of
5 × 105 cells per well, and after incubationwith the treatments (see gen-
eral conditions), the cells were detached and resuspended at a concen-
tration of 1 × 105 cells/ml in the 1X assay buffer provided. Then, 95 μl of
Muse™MitoPotential working solution was added to 100 μl of cell sus-
pension and incubated at 37°C for 20 min protected from light. Then,
5 μl of Muse™ 7‐AAD working solution was added and incubated at
37°C for 5 min; cells were analysed by the Muse™ Cell Analyser.
2.5.5 | Analysis of ERK1/2 phosphorylation
ERK1/2 phosphorylation was analysed by flow cytometry using the
Muse™ MAPK phosphorylation Assay Kit from EMD Millipore
Bioscience.
ERK1/2 phosphorylation was evaluated according to the manu-
facturer's protocol. AsPC‐1 cells were seeded onto 24‐well plates at
a density of 5 × 105 cells per well, and after incubation with the treat-
ments (see general conditions), the cells were detached and suspended
in 500 μl of 1X assay buffer for every 106 cells. Then, fixation buffer
was added in equal parts to the cell suspension (1:1 ratio) and incu-
bated for 5 min on ice. After centrifugation (300 g for 5 min), the
supernatant was removed, and the cells were suspended in 1 ml ice‐
cold permeabilization buffer and incubated for 5 min on ice. After
centrifugation (300 g for 5 min), the supernatant was removed, and
the cells were suspended in 450 μl of 1X assay buffer. Following the
incubation of 5 μl of anti‐ERK1/2, PECy5 antibody to 90 μl of cell sus-
pension for 3 min in the dark at room temperature, 100 μl of 1X assay
buffer was added, and cells were centrifuged (300 g for 5 min) toFIGURE 1 GC chromatogram, MS spectra, and chemical structure of eru
purified after exogenous myrosinase hydrolysis of glucoerucin from Erucadiscard the supernatant. Cells were suspended in 200 μl of 1X assay
buffer and analysed by the Muse™ Cell Analyzer.
2.6 | Statistical analysis
Experiments were performed in triplicate each in three replicates. All
data were expressed as the mean ± standard error; ANOVA (followed
by Bonferroni post test, when required) and student's t test were
selected for the statistical analysis. p < 0.05 was considered represen-
tative of significant differences (software: GraphPad Prism 6.0).3 | RESULTS
3.1 | Production of natural ERU
Natural ERU (0.146 g, 0.878 mmol, 84% yield) was recovered as a light‐
yellow oil from the myrosinase catalysed hydrolysis of glucoerucin
(96% purity, 0.5 g, 1.042 mmol). GC–MS analysis revealed a 97% purity
level based on weight of ERU and the presence of 5‐(methylsulfanyl)
pentanenitrile at 1.7% based on the total peak area (Figure 1).
3.2 | Fluorometric recording of intracellular H2S‐
release
In a previous study, we reported the ability of ERU and other isothio-
cyanates to release H2S in a cell‐free amperometric assay (Citi et al.,
2014). According to these data, ERU exhibited a profile of a slow
H2S‐donor able to increase the release of H2S in the presence of an
excess of L‐cysteine, which was added into the medium (PBS buffer,
pH = 7.4) to mimic a biological environment, rich in thiol groups. In
the current study, we found that ERU releases H2S also inside cells.
In particular, in this experimental assay, the increase of H2S‐releasecin (ERU). GC chromatogram and MS spectra (insert) of natural ERU
sativa seeds [Colour figure can be viewed at wileyonlinelibrary.com]
CITI ET AL. 849inside the AsPC‐1 cell line was followed for 45 min until reaching the
FI plateau (Figure 2a). The area under the curve (AUC) graph allows to
better appreciate that ERU releases H2S in a concentration‐dependent
manner when administered to AsPC‐1 cells at 10, 30, and 100 μM and
that the highest concentration induces a H2S‐release of approximately
40% of that of the natural reference H2S‐donor DADS at the same
concentration (Figure 2b).3.3 | Cell viability
The results, expressed as a percentage of the value recorded for the
vehicle‐treated AsPC‐1, showed a significant and concentration‐
dependent reduction of cell viability in cells treated for 72 hr with
both 30 and 100 μM of ERU, whereas the 10 μM concentration did
not evoke any inhibition. This ERU‐induced inhibition of cell viability
reached an efficacy value of approximately 90% at the highest con-
centration administered (100 μM) and a pIC50 value of 4.43 ± 0.01
(Figure 2c).3.4 | The ERU‐induced inhibition of AsPC‐1 cell
migration
The inhibition of AsPC‐1 cell migration induced by two different con-
centrations of ERU (10 and 30 μM) was assessed by a wound healing
assay at 24, 48, and 72 hr. The 10 and 30 μM concentrations of ERU
were selected because they showed submaximal effects on cell viabil-
ity, and this feature made them more suitable for the wound healing
assay than the 100 μM, which would cause a massive cell death. InFIGURE 2 Fluorometric recording of erucin (ERU)‐mediated H2S release
AsPC‐1 cells after 72 hr of incubation. (a) Fluorometric recordings of H2S
45 min: The increase in H2S is expressed as fluorescence index. (b) The hist
100 μM ERU and 100 μM DADS during 45 min, expressed as AUC. (c) Th
10, 30, and 100 μM ERU. Data are expressed as a percentage of the valu
vertical bars represent the standard error (n = 9). The asterisks indicate a s
***p < 0.001)
TABLE 1 The table shows the percentages of the wound range recorded a
of incubation. Data are expressed as mean ± SEM
Control (%) Vehicle (%)
T24 57.0 ± 1.7 18.3 ± 4.1
T48 92.2 ± 3.5 80.1 ± 2.3
T72 98.0 ± 1.5 87.6 ± 3.7
Note. ERU: erucin.this assay, untreated cells exhibited a time‐dependent wound healing
rate recorded after 24, 48, and 72 hr (Table 1). Treatment with vehicle
decreased the wound healing rate, but only after 24 hr, while after 48
and 72 hr, a recovery of wound healing rate percentage was observed
(Table 1). Finally, treatment with ERU inhibited the migration of AsPC‐
1 cells in a concentration‐ dependent manner, at all timepoints
(Figure 3a). In fact, wound healing ranges and migration rates were sig-
nificantly decreased in AsPC‐1 cells treated with 30 and 10 μM ERU
(Figure 3b; Table 1).3.5 | Inhibition of the cell cycle
After 72 hr of treatment with 30 μM ERU, a significant inhibition of
AsPC‐1 cell cycle progression was observed, with a particular increase
of cells number in the G2/M phase (36.6% ± 3.5 vs. vehicle‐treated
cells in the G2/M phase: 24.0% ± 1.3) and in the S‐phase
(18.1% ± 1.5 vs. vehicle‐treated cells in the S phase: 11.0% ± 0.7)
and a consequent significant reduction of cells in the G0/G1 phase
(35.1% ± 5.0 vs. vehicle‐treated cells in the G0/G1 phase: 59.5% ± 1.8;
Figure 4). Significant effects on the cell cycle have already been
observed in several cancer cell lines treated with natural isothiocya-
nates (Abbaoui et al., 2012).3.6 | Proapoptotic effects of ERU
In this work, we also investigated the ability of ERU to induce mito-
chondrial depolarization (a marker of early apoptosis). As shown in
the graph (Figure 5d), 72 hr of treatment with 30 μM ERU, inducedinside AsPC‐1 cells and inhibition of cell viability induced by ERU in
released by vehicle, 10, 30, and 100 μM ERU and 100 μM DADS for
ograms show the total amount of H2S released by vehicle, 10, 30, and
e histograms show the viability of AsPC‐1 cells treated with vehicle or
e of absorbance recorded for AsPC‐1 cells treated with vehicle. The
tatistically significant difference from vehicle (*p < 0.05, **p < 0.01,
t T0, evoked by vehicle or erucin 10 and 30 μM after 24, 48, and 72 hr
ERU 10 μM (%) ERU 30 μM (%)
19.3 ± 4.6 −11.2 ± 5.2
27.1 ± 5.8 −22.1 ± 1.7
57.5 ± 4.3 −0.1 ± 5.8
FIGURE 3 The inhibition of cell migration assessed by a wound healing assay at 24, 48, and 72 hr. (a) The inhibition of cell migration was
observed in the pictures obtained through the wound healing technique. The effects of vehicle, 10 and 30 μM ERU were observed after 0, 24,
48, and 72 hr of incubation. Pictures were obtained with a 4x objective. (b) The histograms represent the recovery of the wound range, expressed
as a percentage of the wound range recorded at T0, evoked by vehicle or 10 and 30 μM ERU after 0, 24, 48, and 72 hr of incubation. The vertical
bars represent the standard errors (n = 9). The asterisks indicate a statistically significant difference from the value of the T0 wound range
(*p < 0.05, **p < 0.01, ***p < 0.001)
850 CITI ET AL.a decrease in live cells (vehicle: 78.2% ± 4.5 vs. ERU: 60.0% ± 5.0) and
a significant increase in mitochondrial depolarization in both live cells
(vehicle: 7.3% ± 2.6 vs. ERU: 20.8% ± 4.1) and dead cells (vehicle:
12.9% ± 1.5 vs. ERU: 17.8% ± 1.9). The increase of mitochondrial
depolarization in cells treated with ERU is even more evident in graph
7B, in which the whole percentage of mitochondrial depolarization (in
both live and dead cells) is shown (vehicle: 20.3% ± 4.1 vs. ERU:
42.9% ± 2.5; Figure 5e).
In this study, we also investigated a mild stage of apoptosis by
evaluating the effect of ERU treatment on the increase in a well‐
known marker of apoptosis, caspase 3/7, in AsPC‐1 cells after 72 hrof treatment. Recording the caspase 3/7 levels, we obtained a graph
in which we have four different states of cells: live, apoptotic live, apo-
ptotic dead, and dead. In graph 8A, the effect of ERU on caspase 3/7
was compared with the effect of a well‐known chemotherapeutic
proapoptotic drug, paclitaxel at a concentration of 10 μM. After
72 hr, both 30 μM ERU and paclitaxel caused a significant reduction
in the number of live cells (vehicle:78.4% ± 1.3 vs. ERU: 61.9% ± 1.3
vs. paclitaxel: 62.0% ± 1.0), and treatment with paclitaxel resulted in
an increase in the number of apoptotic cells, which was statistically
significant both for apoptotic live (vehicle: 8.1% ± 1.1 vs. paclitaxel:
13.0% ± 1.0) and apoptotic dead cells (vehicle: 9.6% ± 1.4 vs.
FIGURE 4 Inhibition of cell cycle progression after 72 hr. A, b, c: typical cell cycle profiles of AsPC‐1 cells with no treatment (a), after treatment
with vehicle (b), and after treatment with 30 μM ERU (c). D: The histograms indicate the percentage of AsPC‐1 cells in G0/G1, S, and G2/M cell
cycle phases with no treatment (control), treatment with vehicle and 30 μM ERU, after 72 hr of incubation. The vertical bars represent the
standard errors (n = 9). The asterisks indicate a statistically significant difference from the percentage of AsPC‐1 cells in different cell cycle phases
after 72 hr of treatment with vehicle (**p < 0.01)
CITI ET AL. 851paclitaxel: 16.6% ± 0.9). For ERU, the effect was significant only for
apoptotic dead cells (ERU: 20.4% ± 2.0; Figure 5l). Overall, both
30 μM ERU and 10 μM paclitaxel (the positive control) significantly
increased the number of total apoptotic cells (apoptotic dead cells
and apoptotic live cells; vehicle: 17.7% ± 2.5 vs. ERU: 28.7% ± 4.2
vs. paclitaxel: 29.1% ± 0.5), suggesting a relevant role of the
proapoptotic activity of ERU (Figure 5m).3.7 | ERK1/2 phosphorylation in AsPC‐1 cells
The MAPK/ERK pathway represents a fundamental step in cell prolif-
eration, growth, and survival, and, as recently observed for other nat-
ural isothiocyanates, the inhibition of ERK phosphorylation represents
a key target to suppress cancer cell proliferation (Jeong et al., 2017).
Our data, obtained by recording the percentage of total ERK1/2 and
phosphorylated ERK1/2 in AsPC‐1 cells treated for 72 hr with vehicle
or 30 μM ERU, showed reduced levels of phosphorylated ERK1/2
(vehicle: 69.2% ± 2.4 vs. ERU: 56.3% ± 3.5), suggesting a possible
mechanism of action for the antiproliferative effect observed in the
previous experiments (Figure 6a–c).4 | DISCUSSION
Natural isothiocyanates have been known for their anticancer and
chemopreventive effects (Jeon, Yoo, Jang, Jang, & Nam, 2011). Among
natural isothiocyanates, the most studied is SFN, which is present in
Brassica oleracea L. var. italica (broccoli), in particular, and few other
species. ERU is a close analogue of SFN and is the isothiocyanate that
is most present in rocket salad species, particularly in E. sativa Mill.
seeds, in which its content is commonly close to 100 μmol/g (Lazzeri,
Errani, Leoni, & Venturi, 2004). In the human body, ERU can also befound as a metabolite derived from the in vivo reduction of SFN
(Melchini & Traka, 2010). Among the several mechanisms of action
proposed for the chemopreventive and anticancer properties of iso-
thiocyanates, a recent observation of SFN was very promising: At
low concentrations (1–5 μM), SFN was able to promote cell prolifera-
tion, whereas at high concentrations (10–40 μM), SFN inhibited cell
proliferation, cell migration, and angiogenesis in several cancer types
(Bao, Wang, Zhou, & Sun, 2014). This particular behaviour is called
“hormesis,” which has also been used to describe the endogenous
gasotransmitter hydrogen sulfide (Hellmich et al., 2015). Recently,
our research group demonstrated that isothiocyanates, including natu-
ral isothiocyanates derived from Brassicaceae such as ERU, are real
H2S donors that are able to increase their release of H2S in environ-
ments rich in free thiol groups such as biological environments (for
instance, the cell cytosol; Citi et al., 2014; Martelli et al., 2014).
Natural isothiocyanates showed anticancer and chemopreventive
properties with hormetic behaviour. Our group has already demon-
strated that the natural isothiocyanate ERU exhibits hydrogen
sulfide‐releasing properties, and, because there is an intriguing overlap
in the anticancer effect of isothiocyanates and H2S, in this work, we
evaluated the anticancer properties of the natural isothiocyanate
ERU on one of the most aggressive pancreatic adenocarcinoma cell
lines (AsPC‐1).
The first investigation was aimed at detecting the ability of ERU
to release H2S inside AsPC‐1 cells, thus showing the ability to cross
the AsPC‐1 cell membrane and release H2S at the intracellular level.
As clearly highlighted in the experiments carried out with the fluo-
rometric dye WSP‐1, ERU was able to release H2S inside cells in a
concentration‐dependent manner, and this observation led to the
conclusion that ERU acts as a H2S donor at the intracellular level.
Exogenous H2S exhibits antiproliferative effects in different cancer
cell lines (Ma et al., 2018). Consistently, the anticancer effects of slow
FIGURE 5 The effect of erucin (ERU) on early (mitochondrial depolarization) and mild (caspase 3/7 levels) apoptosis in AsPC‐1 cells after 72 hr
of treatment. A, b, c: typical mitochondrial depolarization profiles of AsPC‐1 cells with no treatment (a), after treatment with vehicle (b), and after
treatment with 30 μM ERU (c). (d) Early apoptosis was recorded as mitochondrial depolarization of AsPC‐1 cells after 72 hr of no treatment
(control), treatment with vehicle or 30 μM ERU. For each treatment, four different states of mitochondrial depolarization were examined and
reported as a percentage of the total number of cells: live, live with mitochondrial depolarization, dead with mitochondrial depolarization, and
dead. (e) When the mitochondrial depolarization of live and dead cells was grouped, a higher significance was observed between AsPC‐1 cells
treated with vehicle or 30 μM ERU. F, g, h, i: typical apoptotic profiles of AsPC‐1 cells with no treatment (f), after treatment with vehicle (g), after
treatment with 30 μM ERU (h), and after treatment with 10 μM paclitaxel (i). (l) Mild apoptosis was recorded as an increase in caspase 3/7 levels in
AsPC‐1 cells after 72 hr of no treatment (control), treatment with vehicle, treatment with 30 μM ERU, or treatment with 10 μM paclitaxel. For
each treatment, four different states of cell apoptosis were examined and reported as a percentage of the total number of cells: live, apoptotic live,
apoptotic dead, and dead. The vertical bars represent the standard errors (n = 9). The asterisks indicate a statistically significant difference from the
percentage of AsPC‐1 cells in different degrees of apoptosis after the 72 hr of treatment between vehicle‐, ERU‐treated cells, or paclitaxel‐treated
cells (*p < 0.05, **p < 0.01, and ***p < 0.001)
852 CITI ET AL.H2S‐donors, such as GYY4137 (one of the pioneer compounds of this
class), have been reported; GYY4137, a hydrogen sulfide (H₂S) donor,
shows potent anti‐hepatocellular carcinoma activity by blocking the
STAT3 pathway (Lu, Gao, Huang, & Wang, 2014). Even other natural
H2S donors, such as acetyl deacylase disulfide, have been reported
to promote H2S‐mediated anticancer effects (De Cicco et al., 2017).
On the basis of these premises, we hypothesize that the H2S‐releasing
effects of ERU could be a reasonable mechanism for its anticancer
effects. Consistently in this work, 72 hr of incubation with ERUproduced a concentration‐dependent inhibition of AsPC‐1 cell viability
with a pIC50 value of 4.43 ± 0.01. In addition to the antiproliferative
effect, ERU also significantly inhibited AsPC‐1 migration. The AsPC‐
1 cell line, derived from ascitic metastasis of an adenocarcinoma of
the head of the pancreas, represents a reliable model to verify the
anti‐migration properties of ERU. The reduction of wound healing
was greatly impaired by ERU in a concentration‐dependent manner.
The concentration of 30 μM ERU could evoke an almost maximal
effect, leading to an almost full abolishment of AsPC‐1 cell migration.
FIGURE 6 p‐ERK1/2 in AsPC‐1 cells after 72 hr of treatment with erucin (ERU). A, b: typical ERK1/2 phosphorylation profiles of AsPC‐1 cells
after treatment with vehicle (a) and after treatment with 30 μM ERU (b; the % of inactivated cells indicates the nonphosphorylated ERK1/2 levels,
the % of activated cells indicates the p‐ERK1/2 levels, and the % of nonexpressing cells indicates cells not expressing ERK1/2). (c) The action of a
72 hr treatment with 30 μM ERU on the MAPK/ERK pathway of AsPC‐1 cells was recorded, and the amount of total ERK1/2, phosphorylated
ERK1/2, and the ratio between phosphor‐ERK1/2 and total‐ERK1/2 were calculated comparing the ERU‐treated and vehicle‐treated cells. The
vertical bars represent the standard errors (n = 9). In the second set of histograms, the asterisks indicate a statistically significant difference
compared with the percentage of phosphorylated ERK1/2 in vehicle‐treated AsPC‐1 cells after 72 hr (*p < 0.05). In the third set of histograms, the
asterisks indicate a statistically significant difference compared with the percentage of the phosphor‐ERK1/2/total‐ERK1/2 ratio in vehicle‐
treated AsPC‐1 cells after 72 hr (*p < 0.05)
CITI ET AL. 853This property of ERU has great importance in counteracting the met-
astatic process of particularly aggressive cancers, such as pancreatic
adenocarcinoma. As already shown for other isothiocyanates and in
other types of cancer, ERU demonstrated a clear ability to arrest the
cell cycle in the G2/M phase and in the S phase, showing a conse-
quent reduction of cells in the G0/G1 phase. This important property
was coupled with another fundamental feature of a chemopreventive
anticancer drug: ERU induced significant proapoptotic effects, which
emerged when observing both early and mild stages of apoptosis. In
fact, we recorded a marked increase in mitochondrial depolarization
in AsPC‐1 cells treated with ERU for 72 hr. We also found a significant
increase in caspase 3/7 levels as a marker of cell apoptosis after ERU
incubation for 72 hr. For the final investigation, we focused on the
phosphorylation status of ERK1/2. In fact, pancreatic cancer cell lines
are characterized by frequent mutations in the KRAS (v‐Ki‐ras2 Kirsten
rat sarcoma viral oncogene homologue) gene, and in particular, AsPC‐1
cells showed a mutation in the 12 codon of KRAS. This mutation led to
a hyperactivation of KRAS with a consequent hyperphosphorylation
of the downstream kinases (Deer et al., 2010). On this basis, we
investigated the effect of 72 hr of treatment with 30 μM ERU on
the phosphorylation of ERK1/2 in AsPC‐1 cells. ERU did not affect
the expression of ERK1/2 but led to significantly lower levels of
phosphorylated ERK1/2. Because ERK1/2 is involved in the regulation
of cell proliferation and cell survival, this ERU‐mediated effect may
contribute to the anticancer activity of this isothiocyanate.5 | CONCLUSIONS
This work delineates the chemopreventive and anticancer profile of ERU
in pancreatic adenocarcinoma. Our group first described natural and
synthetic isothiocyanates as molecules that are able to release H2S. In
this study, we demonstrated that treatment with ERU promotes asignificant intracellular increase of this gasotransmitter in AsPC‐1 cells.
Moreover, high concentrations of ERU (30–100 μM) inhibited AsPC‐1
cell viability. ERU also inhibited cell migration and altered the AsPC‐1 cell
cycle, reducing G0/G1 phase and increasing G2/M and S phases,
demonstrating proapoptotic effects in the early and mild stages. Finally,
ERU administration was associated with reduced levels of phosphory-
lated ERK1/2. This feature is particularly important in pancreatic AsPC‐
1 cells because AsPC‐1 are characterized by an activating mutation in
KRAS that determines the hyperphosphorylation of ERK1/2 kinase,
leading to pancreatic cancer cell proliferation, growth, and survival.
Despite the wide characterization of ERU anticancer activities in human
pancreatic adenocarcinoma, this study did not include in vivo experi-
ments on animal xenograft models. This aspect is interesting, has many
implications, and will be the main topic of future work. In conclusion,
these data highlight the interesting biological properties of ERU, which
can pave the way to a potential pharmacological exploitation of this
compound and its analogues and facilitate the development of intriguing
perspectives for nutraceutical products derived from E. sativaMill.
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